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ABSTRACT 
THE ROLE OF CYCLOSPORINE IN LIVER 
DISEASE AFTER RENAL TRANSPLANTATION 
Terry June Watnick 
1987 
The role of cyclosporine in liver disease after renal transplan¬ 
tation was evaluated. In a retrospective analysis, liver function 
tests (LFTs) were compared in cyclosporine-treated versus 
azathioprine-treated renal transplant recipients. In one type of 
analysis, the incidence and causes of elevated transaminases (defined 
as SCOT or SGPT greater than 41 IU/L on at least two consecutive 
occasions) were determined in 19 cyclosporine-treated renal 
transplant recipients versus 15 azathioprine-treated patients. 
Forty-seven percent of the cyclosporine group (9 patients) versus 40% 
(6 patients) of the azathioprine group (p=NS) developed abnormal 
transaminases during the first 4 to 6 post-transplant months. Peak 
transaminase levels varied from one and one-half times to ten times 
normal. Cytomegalovirus (CMV) was the most frequently identifiable 
cause of hepatic dysfunction (7 of 15 patients). 
In another type of analysis, mean monthly SGOT, SGPT and total 
bilirubin were compared in the two treatment groups. There was no 
consistent difference in mean SGOT or SGPT between the two groups. 
Neither SGOT nor SGPT was correlated with serum trough cyclosporine 
levels. In contrast, total bilirubin levels tended to be higher, 
although still within the normal range, in cyclosporine-treated 
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patients versus azathioprine-treated patients. The difference 
was statistically significant in month 1 (.56 ± .04 vs .42 ± .05, p = 
.04) and in month 3 (.68 ± .07 vs .44 ± .05, p = .01). Both direct 
and total bilirubin levels were correlated with cyclosporine trough 
levels during the first two months when cyclosporine levels were 
highest. 
We conclude that cyclosporine therapy causes hepatic dysfunction 
characterized by mild hyperbilirubinemia. This effect is most 
prominent in the early post-transplant period when cyclosporine 
levels are highest. If mean serum cyclosporine trough levels 
(measured by high-pressure liquid chromatography) are kept below 200 
ng/ml, however, this is of little clinical significance since 
bilirubin levels remain within the normal range. Because of the many 
causes of viral hepatitis prevalent during the first six post¬ 
transplant months, elevated transaminases alone are not specific for 
cyclosporine hepatotoxicity. Multiple etiologies must be at least 




Thank you to: 
My sister, Paula, for helping me with the very professional 
graphs. 
Sammy Carr, for typing this manuscript with its many revisions. 
Peggy Bia, for teaching me the ins and outs of clinical research 
and for showing me how much can be accomplished with creativity and 
determination. 
Jodi Halpern, for being my closest friend for the past five 
years. 
KDC, for helping me to maintain my principles in a sometimes 
hostile environment. 
My family, Arthur, Clara and Paula, for listening sympathetically 
to all my troubles for almost thirty years. 

Dedication 
To Marc and Ezra - We made it 
Five down and three to go. 

TABLE OF CONTENTS 
Page 
Literature Review . 1 
Purpose.23 




Tables and Figures.47 
Table 1: Baseline Characteristics . , . . 48 
Table 2: Etiology of Elevated LFTs in Transplant 
Recipients Treated With Azathioprine . . . . . . 49 
Table 3: Etiology of Elevated LFTs in Transplant 
Recipients Treated with Cyclosporine . . . . . . 50 
Table 4: Mean Monthly Cyclosporine Levels in Patients 
With Elevated vs. Normal Transaminases . . . , . . 51 
Table 5: Correlation of Cyclosporine Levels With 
Direct and Total Bilirubin Levels ....... . . 52 
Figure 1: Mean Monthly LFTs in Cyclosporine-Treated 
Patients vs. Azathioprine-Treated Patients . , . . 53 
Figure 2: Mean Monthly Cyclosporine Trough Levels . . . . . 54 
Appendix: Clinical Data for Nine Cyclosporine-Treated 
Patients and Six Azathioprine-Treated Patients 





Cyclosporine, a potent immunosuppressive agent, is a cyclic 
endecapeptide first isolated from two strains of the fungus 
Tolypocladiurn inflatum Gams (2,3). Cyclosporine is unique because, 
unlike other immunosuppressive drugs, it acts directly on the 
immunoregulatory responses of helper T cells without causing 
generalized myelosuppression (1). 
Cyclosporine is a lipophilic substance that can be given orally 
or parenterally (3). After oral administration, peak serum levels of 
the drug are reached within 3 to 4 hours (4). Even with a fixed 
dosage regimen based on body weight, however, there is a wide 
variation in blood concentrations of the drug due to erratic 
absorption by the GI tract (4). Because of its hydrophobic nature, 
cyclosporine has a large volume of distribution and after chronic 
administration tends to accumulate in the liver, kidney and fat 
stores (4,7,8). Thus, with continued use, there is a decreased 
dosage requirement necessary to maintain constant serum cyclosporine 
levels (9). In whole blood, in the concentration range from 25 to 
500 ng/ml, the uptake of cyclosporine by erythrocytes is about 50% 
while leukocytes take up 10% to 20% (4). Of the amount of drug 
remaining in the plasma, 90% is protein bound mainly to lipoproteins 
(8). The uptake of cyclosporine by erythrocytes is a temperature 
dependent process and when the temperature is lowered from 37°C to 21 
*t, cyclosporine diffuses into blood cells (4). 
Cyclosporine is metabolized in the liver by the cytochrome P 
450 
oxidase system and drugs interacting with this system can raise or 
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lower blood levels of the drug (5). Cyclosporine is excreted 
primarily in the bile while only 6% of the parent drug and its 
metabolites are excreted in the urine (4). Not all the metabolites 
of cyclosporine have been well characterized but they are thought to 
have minimal immunosuppressive properties when compared with the 
parent compound (5). The toxicity of various metabolites has yet to 
be determined but the major human metabolite of cyclosporine has no 
nephrotoxicity in rats (7,12). 
Because there is little correlation between dosage and blood 
concentrations of cyclosporine and because toxicity is thought to be 
concentration dependent, monitoring of drug levels has become 
important in the clinical management of patients receiving 
cyclosporine immunosuppression. There are currently two methods 
available for this analysis. High-performance liquid chromatography 
(HPLC) is expensive and labor intensive but is specific for the 
parent compound (7). The other method, a radioimmunoassay (RIA) 
using a kit made by Sandoz, is inexpensive and can be used to perform 
a large number of assays in a relatively short period of time (10). 
The antibody provided in the kit, however, is nonspecific and detects 
both the parent compound and some of its metabolites (10). Thus, 
cyclosporine levels determined by RIA can be 2 to 4 times higher than 
those measured by HPLC and the difference can vary during the dosage 
interval (10). In order to minimize this source of variation, most 
centers monitor cyclosporine trough levels. In general, cyclosporine 
levels measured by RIA and HPLC parallel each other and either method 
is adequate as long as the appropriate reference scale is used 
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(13,14). The one situation in which measurements by RIA may be 
unreliable is in the setting of liver dysfunction. Burckart et al., 
reported elevated RIA:HPLC ratios in pediatric recipients of 
orthotopic liver transplants in conjunction with deteriorating 
hepatic function, poor bile flow and elevated liver enzymes (15). 
Since cyclosporine metabolites are excreted in the bile (with little 
unmetabolized cyclosporine), cholestasis may cause elevated blood 
levels of these metabolites detected by RIA but not HPLC (15). 
For either method, whole blood, serum or plasma may be used. 
Because cyclosporine can accumulate inside blood cells in a 
temperature dependent fashion, levels in whole blood are always 
higher than serum or plasma. The ratio of whole blood cyclosporine 
levels to serum or plasma is about 2:1 but may vary between patients 
and according to hematocrit (7,10). Many centers prefer to use whole 
blood in assaying cyclosporine levels in order to avoid having to 
equilibrate the sample at a set temperature before processing it. 
This also makes it easier to compare data between centers. Other 
investigators, however, prefer to use plasma or serum levels because 
they are not subject to variation in hematocrit and leukocyte number 
and may more accurately reflect "free" concentrations (16). 
As experience with cyclosporine has been gained, it has become 
evident that drug levels necessary to achieve immunosuppression 
without toxicity decrease with time after transplantation (38,39). 
Data from several centers suggest that serum trough cyclosporine 
levels (RIA) should be kept under 200 ng/ml especially in long-term 
treated patients (7,9,14,38,39). 
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Cyclosporine was first used in renal transplantation by Caine, et 
al., in 1978 (11). Since then cyclosporine has been shown to be just 
as, if not more, effective than conventional immunosuppressive 
therapy. In three large, randomized prospective trials, one year 
cadaver allograft survival rates in cyclosporine-treated patients 
were 72% in the European multicentre trial, 80.4% in the Canadian 
multicenter trial and 84% in the University of Minnesota trial. 
One-year cadaver graft survival in patients treated with azathioprine 
and prednisone at these centers was 52%, 64% and 79%, respectively 
(17,18,19). The difference was statistically significant only in the 
first two trials. Improved results with azathioprine in the last 
center were probably due to the addition of other treatment 
modalities such as anti lymphocyte globulin (ALG), pre-transplant 
splenectomy and multiple transfusions. Similar results with 
azathioprine have been achieved by other investigators using similar 
protocols (20,21). 
All three groups have followed their patients for at least three 
years and have demonstrated continued success with cyclosporine 
(22,23,24). 
In addition to improved graft survival, other advantages of 
cyclosporine in comparison with azathioprine include a decrease in 
the incidence of acute rejection, a decrease in the incidence of 
infection, a steroid sparing effect and a decrease in time spent in 
the hospital (18,19,25,26,37). Also, cyclosporine rarely causes 
leukopenia (37). 

Cyclosporine is not without toxicity. Minor but common side- 
effects include gingival hyperplasia, hypertrichosis, gastrointes¬ 
tinal symptoms, fine tremor and paresthesias (3). Lymphoprolitera¬ 
tive disorders, thought to be associated with Epstein-Barr virus 
(EBV) infection, occur in cyclosporine-treated patients but the risk 
is no greater than with conventional immunosuppressive therapy (3). 
Lymphomas seen in the course of treatment with cyclosporine tend to 
resolve with cessation of therapy (3). The most attention has been 
focused on the nephrotoxicity of cyclosporine especially in kidney 
allograft recipients where it can make the diagnosis of rejection 
difficult. Renal dysfunction caused by cyclosporine can be acute or 
chronic and generally responds to dosage reduction. Metabolic 
acidosis, with hyperkalemia and hypertension, may also be results of 
cyclosporine induced nephrotoxicity (2,3). Although renal allograft 
recipients treated with cyclosporine consistently have higher serum 
creatinines than azathioprine-treated patients, renal function does 
not appear to deteriorate with time (23,25,26,27). 
Of all the major side effects of cyclosporine, hepatotoxicity has 
been the least well characterized. In the initial pilot studies by 
Caine, et al., in 1978 and 1979, it was noted that almost all 
patients treated with cyclosporine had abnormalities in liver 
function consisting of elevated bilirubin, alkaline phosphatase (AP) 
and in some patients, transaminases as well (11,28). Since then it 
has been observed that elevated AP in these patients is most often of 
osseous origin and therefore probably not due to cyclosporine 
hepatotoxicity (29,44,45). 

Subsequent to these initial studies, investigators conducting 
clinical trials have continued to note elevated liver function tests 
(LFTs) in renal transplant recipients treated with cyclosporine. The 
incidence of hepatic dysfunction in these trials has ranged from 3.6% 
to 42% (2,18,19,30,32,34,35,36). It is unclear whether cyclosporine- 
induced hepatotoxicity is manifested by elevations in bilirubin 
alone, transaminases alone or both. Some authors have described 
hyperbilirubinemia as being characteristic of cyclosporine hepato- 
toxicity (34,35) but most have also noted accompanying elevations in 
transaminases (2,18,31,33,36). Differences may be due to a failure 
in separating those patients with other reasons for hepatic dysfunc¬ 
tion. It is generally agreed that cyclosporine-induced hepatotoxici- 
ty tends to occur well within the first six post-transplant months 
(2,31,34,36) and in most cases resolves with dosage reduction rarely 
necessitating discontinuation of the drug (2,18,30,31,34,36). 
The larger, randomized prospective clinical trials described 
previously have compared liver function in cyclosporine-treated 
patients and azathioprine-treated patients. Najarian, et al., at the 
University of Minnesota (19), found that the frequency of elevations 
in serum bilirubin not due to infectious hepatitis was the same in 
the cyclosporine group (17% of 121 patients) and in the azathioprine 
group (15% of 109 patients). Furthermore, between one and one and 
one-half years post-transplantation, there was no statistically 
significant difference in serum bilirubin or SGOT between the two 
groups. These findings are similar to those of the Canadian 
Multicenter Trial (18) where approximately 4% of each group (103 

cyclosporine patients and 107 azathioprine patients) had evidence of 
hepatic dysfunction. In the cyclosporine group, elevations in LFTs 
(bilirubin, transaminases and gamma-glutamyl transpeptidase) were 
associated with cyclosporine trough levels above 1000 ng/ml whereas 
in the azathioprine group other causes were found (hypoxic liver 
damage, CMV infection, trimethoprim-sulfamethoxazole toxicity and 
cholelithiasis). There was no difference in the mean level of 
bilirubin or aspartate aminotransferase (AST) between the two 
groups. Cyclosporine-treated patients had a higher mean level of AP 
but the enzyme was not fractionated. It is thus unclear whether 
elevated enzyme levels were of hepatic origin. 
In the European multicentre trial (17,35), unlike the studies 
cited above, there was a higher incidence of hyperbilirubinemia in 
the cyclosporine group (20% of 117 patients) versus the azathroprine 
group (3% of 115 patients). At one year post-transplantation, 
cyclosporine-treated patients had higher mean levels of bilirubin, 
AST and AP than azathioprine-treated patients. Unfortunately, as in 
other studies, AP was not fractionated. There was no difference in 
the levels of alanine aminotransferase (ALT) or gamma-glutamyl 
transpeptidase. 
The increased incidence of hyperbilirubinemia in the European 
trial versus the University of Minnesota trial may in part be due to 
higher serum levels of cyclosporine in the former. Although serum 
drug levels were not reported in either study, in the University of 
Minnesota trial, a lower initial dose of cyclosporine was used and 
dosages were tapered more rapidly. Other reasons for the disparity 
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between these trials include possible differences in the frequency 
with which LFTs were measured and in the methods used to identify 
patients with causes of hyperbilirubinemia other than cyclosporine. 
Because these papers did not focus on hepatotoxicity, neither of 
these parameters was adequately described. 
The observation of elevated LFTs in cyclosporine-treated patients 
has prompted a few centers to examine the hepatotoxicity of 
cyclosporine in a more systematic fashion. Several factors alluded 
to above have also made evaluation of these reports difficult. There 
are many causes of abnormal liver function tests in the immediate 
post-transplant period, as will be discussed in detail later. In 
many studies it was unclear how cyclosporine-induced hepatotoxicity 
was distinguished from other causes of hepatitis. Most authors 
focused on abnormalities in one enzyme, bilirubin, without looking at 
transaminases and did not specifically state how often LFTs were 
measured. This could be important especially in the early 
post-transplant period when cyclosporine levels tend to be high and 
episodes of transient hepatotoxicity might be missed. Lastly, 
because centers used different definitions of hepatotoxicity and 
different techniques to measure cyclosporine levels, it was difficult 
to compare results. 
One set of reports concentrated on the hyperbilirubinemia 
characteristic of cyclosporine-induced hepatotoxicity. Laupacis, et 
al., looked at 21 cadaveric renal transplant recipients treated with 
an initial cyclosporine dose of 17.5 mg/kg/day further adjusted to 
achieve serum trough levels (by RIA) of 100-400 ng/ml and two-hour 
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post dose levels of 400-1000 ng/ml (41). All patients had 
cyclosporine levels and bilirubin levels measured daily in the 
hospital. Four patients (19%) had one episode of hyperbilirubinemia 
(serum bilirubin greater than 1.0 mg/dl for 3 days with no other 
apparent cause) within two weeks of transplantation lasting 3 to 6 
days. A causal relationship was observed between hyperbilirubinemia 
and cyclosporine levels in these patients. That is, cyclosporine 
trough levels and 2-hour post-dose levels rose prior to the serum 
bilirubin and fell, with dose reduction, prior to normalization of 
bilirubin. The authors conclude that cyclosporine-induced hyper¬ 
bilirubinemia occurs with trough and 2 hour post-dose cyclosporine 
levels greater than 400 ng/ml and 1000 ng/ml respectively. In this 
study, although cyclosporine and bilirubin levels were documented 
carefully while patients were in the hospital (probably at least two 
weeks), there is no mention made of how often LFTs were measured 
after this period and whether or not there were any other LFTs 
elevated. Also, it is not stated which other causes of hyperbili¬ 
rubinemia were excluded. 
Loertscher, et al., studying only 8 patients receiving 
cyclosporine (17 mg/Kg/day for 14 days with subsequent monthly 
reductions of 2 mg/Kg/day) found that 5 patients developed simul¬ 
taneous increases in bilirubin and cyclosporine within 5 days of 
transplantation (40). Two additional patients, however, had hyper¬ 
bilirubinemia without elevations in cyclosporine trough levels later 
in the post-transplant course. One patient had a high cyclosporine 
trough level without hyperbilirubinemia. These authors conclude that 
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hyperbilirubinemia is caused by cyclosporine therapy but is indepen¬ 
dent of serum drug levels. 
Klintmalm, et al., obtained similar results in a larger group of 
66 recipients of cadaveric kidneys who recieved 17 mg/Kg/day of 
cyclosporine for at least 8 weeks post-operatively (42). Eleven of 
13 (19.6%) patients who displayed hyperbilirubinemia (bilirubin 
greater than 2.0 mg/dl) developed it early between 2 weeks and 2 
months post-transplant when doses in those patients were still high 
(mean 17.7 ± 1.1 mg/Kg/day). Three patients had hyperbilirubinemia 
greater than 6 months post transplant when cyclosporine doses were 
less than 10 mg/Kg/day. No cyclosporine levels were available but 
all cases resolved with dosage adjustments. One-half of the patients 
had normal transaminases (SGOT and SGPT) while in the other half 
there were elevations to 3 times normal, suggesting that these 
enzymes are not specific for cyclosporine-induced hepatotoxicity. AP 
levels in patients with hyperbilirubinemia were normal or slightly 
above normal. It was mentioned that one of the 13 patients was HBsAg 
positive prior to transplantation while 7 patients were on other 
drugs with hepatotoxic potential (cimetidine, isoniazid). None of 
these drugs was changed during toxic episodes. It was not stated 
whether other causes of viral hepatitis were investigated. 
Another paper by Klintmalm, et al., also suggests that bilirubin 
is the more important parameter in reflecting hepatotoxicity (39). 
Of 48 renal transplant recipients treated with cyclosporine (15 
mg/Kg/day and then tapered), 18 had isolated increases in ALT while 7 
had increases in ALT and bilirubin (ALT greater than 25 umol/L, 
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bilirubin greater than .70 ukat/L with no other possible explana¬ 
tion). Isolated increases in ALT occurred during the first month in 
15 patients and between 2 and 12 months in 3 patients. The mean 
cyclosporine plasma level (RIA) was not higher in these patients and 
elevations resolved within 2 weeks without dosage adjustments. Of 
the 7 patients (14.6%) with increases in ALT and bilirubin, 5 
occurred in the first post-transplant month. The mean cyclosporine 
trough plasma level was higher during these episodes (732 ± 102 
ng/ml) than during normal liver function (226 ± 26 ng/ml, p < .01). 
The authors conclude that increases in ALT alone are of little 
clinical significance while increases in bilirubin and ALT require 
dosage adjustment for resolution. 
The results of Keown, et al., confirm the association between 
cyclosporine levels and hyperbilirubinemia (9,43). Of 72 
cyclosporine-treated patients (dose not stated), 6 patients (8.3%) 
developed hyperbilirubinemia (bilirubin greater than 1.0 mg/dl) all 
during the first three post-transplant weeks. Serum cyclosporine 
levels (by RIA) rose prior to the onset of hyperbilirubinemia, from 
65 ± 66 ng/ml to 630 ± 112 ng/ml. All cases resolved after the 
dosage was decreased. Linear regression analysis showed that serum 
bilirubin was directly correlated with cyclosporine trough level 
2 
(r - .58, p = .001). It was not stated whether other LFTs were 
elevated as wel1. 
Findings in recipients of other organs also point out the 
significance of hyperbilirubinemia. Schade, et al., retrospectively 
studying 30 cyclosporine-treated recipients of heart transplants, 
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found that serum bilirubin reached a peak elevation, 2.5 times normal 
at about 2 weeks post-transplant while pre- and post-transplant SGOT, 
SGPT and AP were not significantly different (48). Interestingly, in 
11 subjects, fasting serum bile salt levels were elevated (despite 
normal AP) indicating pronounced cholestasis. The mean cyclosporine 
blood level (HPLC) in these patients was 474 + 47 ng/ml and there was 
no correlations between drug levels and serum bilirubin or bile salt 
levels. 
Atkinson, et al., retrospectively studying bone marrow transplant 
recipients, found that 10 of 21 patients had cyclosporine associated 
hyperbilirubinemia (49). Eight additional patients had other causes 
for their elevated bilirubin levels, for example, acute graft-versus- 
host disease of the liver, sepsis and hemolysis. It was not clear 
that viral hepatitides such as cytomegalovirus (CMV) were ruled out. 
Cyclosporine-induced hyperbilirubinemia was also associated with an 
increase in ALT (mean = 109 ± 47 IU/L) but AP levels were only 
minimally elevated. Cyclosporine trough levels were correlated with 
bilirubin levels (correlation coefficient = .36). The mean day of 
onset of hepatotoxicity was 18.5 ± 18 with a mean duration of 72 ± 
47.5 days. This prolonged hepatic dysfunction in the face of 
cyclosporine dose reductions suggests that perhaps patients with 
viral hepatitis may have been included in this group. 
Only the group in Birmingham has made an attempt to compare LFTs 
in cyclosporine- and azathioprine-treated patients (44,45). In a 
randomized, prospective study, 35 patients were treated with a 
cyclosporine dose of 15 mg/Kg/day with reduction to 12 mg/Kg/day at 1 
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month post-transplant; 31 patients were treated with azathioprine 
(44). At least some patients had LFTs measured at weekly intervals 
for the first 12 post-transplant weeks (45). Mean bilirubin levels 
were significantly higher in the cyclosporine-treated patients for 
the first 3 post-transplant months but hyperbilirubinemia was 
uncommon. AST levels were significantly higher in the cyclosporine 
group only during the first post-transplant month. Mean AP levels 
were significantly higher in cyclosporine-treated patients at all 
times but in only one patient was it due to the hapatic isoenzyme. 
Five patients (14%) in the cyclosporine group and nine patients (29%) 
in the azathioprine group developed abnormalities in bilirubin or 
transaminases (bilirubin greater than 22 umol/L, AST greater than 35 
IU/L). In the cyclosporine group, elevations were due to CMV (2 
patients), herpes simplex (HSV), congestive cardiac failure and 
possible cyclosporine toxicity although in this patient, LFTs did not 
normalize with dose reduction. In the azathioprine group the reasons 
were sepsis (3 patients), viral encephalitis, hepatitis B virus (HBV) 
infection and 4 cases were unexplained, possibly due to azathioprine 
or isoniazid. The authors conclude that infection was the most 
common cause of liver dysfunction following renal transplantation and 
that cyclosporine has no marked hepatotoxicity. Because bilirubin 
was higher in the cyclosporine group (although still within the 
normal range) during the first 3 months, however, it was concluded 
that cyclosporine is responsible for subclinical hepatic dysfunc¬ 
tion. One possible reason for the different conclusions reached by 
these authors is the frequency with which LFTs were measured. 
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Although the timing of elevated LFTs was not specifically stated, it 
is possible that the early hyperbilirubinemia that occurred within 
the first post-transplant days in other studies was missed. In 
addition, the initial cyclosporine dose administered by the 
Birmingham group was lower than in the studies discussed previously. 
Only two centers have found elevated transaminases to be 
indicators of cyclosporine-induced hepatotoxicity. In an abstract, 
Maddux, et al., reported their study of 46 renal transplant 
recipients treated with cyclosporine (12-14 mg/Kg/day for 7 to 14 
days followed by titration to whole blood trough levels of 400-800 
ng/ml (46). Six patients were excluded because of insufficient 
follow-up, sepsis or viral hepatitis. Of the remaining 40 patients, 
16 (40%) had elevated LFTs, mainly SG0T (62%) and SGPT (88%), an 
average of 41 days post-transplant. Only 1 patient had hyperbili¬ 
rubinemia. Patients with elevated LFTs had higher whole blood trough 
levels (920 ng/ml) than patients with normal LFTs (447 ng/ml, p < 
.05) and elevations resolved after dosage reduction. In this study, 
it is not stated how often LFTs were measured and it is possible that 
early hyperbilirubinemia was missed. Alternatively, not only were 
lower doses of cyclosporine used initially, but trough levels were 
monitored so that hyperbilirubinemia due to early elevations in 
cyclosporine levels may have been avoided. Patients with sepsis and 
viral hepatitis were excluded but which types of hepatitis were 
tested for, i.e., CMV, was unclear. Although elevations in LFTs 
resolved with dosage reduction, improvement occurred in a mean time 
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of 60 days. This could easily have been due to resolution of another 
disease process. 
The most comprehensive series reported in the literature is that 
of Lorber, et al., who followed 466 cyclosporine-treated renal 
transplants (47). Because of its depth, this study deserves detailed 
consideration. 
Several cyclosporine protocols were used and many patients 
received a continuous IV cyclosporine infusion (3 mg/Kg) during the 
first 48 post-transplant hours. Oral cyclosporine at 14 mg/Kg/day 
was resumed and tapered. After 14 days, the cyclosporine dose was 
adjusted to maintain serum trough levels of 50-200 ng/ml (RIA). 
Hepatoxicity was defined as bilirubin greater than or equal to 1.5 
mg/dl and/or SGOT or SGPT greater than or equal to 50 IU/L when other 
potential reasons were excluded. Isolated elevations in AP or LDH 
were not considered to represent hepatotoxicity. Hepatotoxicity was 
managed by decreasing the cyclosporine dose to achieve trough levels 
less than or equal to 100 ng/ml. 
Of 466 patients, 228 or 49% had at least one episode of elevated 
LFTs. Of those patients with hepatic dysfunction, 110 (48%) had 
hyperbilirubinemia, 108 (47%) had an elevated SGOT and 167 (73%) had 
an elevated SGPT. Only 1 patient had an isolated abnormality while 
most (140/228) had elevations in bilirubin or transaminases with 
increases in AP and LDH. Most patients (187/228) had isolated 
episodes of hepatotoxicity while 41 patients had recurrent or 
persistent elevations in LFTs. The mean cyclosporine level was 226 + 
17 ng/ml in hepatotoxic patients but was not compared to the level in 
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those patients with normal LFTs. Hepatotoxic patients did have 
increased bioavailability and decreased cyclosporine clearance when 
compared with the other patients. In 214 of 228 patients (94%) 
hepatoxotoxicity began during the initial 90 post-transplant days. In 
fact, 50 patients exhibited elevated LFTs during the 48 hours of IV 
infusion and 61% of hepatotoxic episodes began within the first seven 
days when cyclosporine doses were highest. Dosage reduction resulted 
in resolution in 81% of the patients including all 14 patients whose 
elevated LFTs began after 90 days. 
The incidence of hepatotoxicity detected in this series exceeds 
that found by any other group. There are several possible reasons. 
First, unlike other protocols, patients were treated with continuous 
infusions of cyclosporine, presumably leading to higher levels of the 
drug. In fact, almost 1/4 of patients with hepatotoxicity 
experienced it during this period. Although not explicitly stated, 
LFTs were probably measured daily in the hospital allowing for 
increased detection of abnormalities. It would be interesting to 
know whether elevations occurring during the first post-transplant 
week were predominantly hyperbilirubinemia, as found in other 
studies. Lastly, it is unclear from this paper how many patients may 
have had other causes for abnormal LFTs. For example, of those 
patients with hepatotoxicity, 16 had a history of polycystic disease, 
16 had a history of "hepatitis," 4 had cholelithiasis, 3 had peptic 
ulcer disease and 3 had pancreatitis. Although it was stated that 
these problems were corrected prior to transplantation, they could 
conceivably continue to cause elevated LFTs and additional 

17 
investigation might be necessary to rule this out. Furthermore, it 
would not be at all inconsistent to assume that the 32 patients with 
recurrent or persistent LFT abnormalities had non A- non B-hepatitis 
which is the most common cause of hepatitis in renal transplant 
recipients (51,62). In addition, although the authors state that 
patients with viral hepatitis were excluded, it might be useful to 
know which viral infections were tested for in these patients, i.e., 
CMV, EBV, HBV, HSV. 
All of the other studies previously discussed have concluded that 
cyclosporine-induced hepatotoxicity is without sequelae. Lorber, et 
al., however, found that 11 (5%) cyclosporine-treated patients with 
hepatotoxicity developed biliary calculous disease detected between 8 
and 33 months post-transplant. Nine of the patients previously had 
recurrent or persistent cyclosporine "hepatotoxicity." The authors 
suggest that cyclosporine hepatotoxicity may be linked to biliary 
calculous disease. No cholelithiasis was seen in 279 azathioprine- 
treated patients at the same institution. These suggestions must be 
regarded cautiously since the incidence of biliary calculous disease 
in cyclosporine-treated patients without hepatotoxicity was not 
reported. As the authors suggest, longer follow-up of this cohort is 
necessary. 
In sum, the incidence of cyclosporine-induced hepatotoxicity has 
varied depending on the definition applied and the rigor with which 
abnormalities have been searched for. Authors that have obtained 
LFTs frequently in the early post-transplant period when cyclosporine 
levels vary widely have found a high incidence of hepatotoxicity. 
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There seems to be general agreement that cyclosporine liver toxicity 
during this period is manifested by elevations in serum bilirubin 
often associated with increases in transaminases. These 
abnormalities which are directly related to blood levels of the drug 
resolve with dosage reduction. A minority of patients can develop 
hyperbilirubinemia after this period which is still reversible with 
dosage reduction. Often, however, serum cyclosporine levels are not 
absolutely elevated. 
Elevations in LFTs after the first few post-transplant weeks have 
been attributed to cyclosporine but the analysis of many authors has 
been confounded by a failure to consider the many other causes of 
post-transplant hepatitis. Post-transplant hepatitis is a common 
phenomenon and long before the advent of cyclosporine, liver 
dysfunction was noted to occur in 7 to 67% of renal transplant 
recipients with 6 to 16% of these patients developing chronic 
hepatitis (50,51). The significance of these figures cannot be 
underestimated since in one study the most common cause of mortality 
in renal transplant recipients with grafts surviving more than 5 
years was chronic liver disease (52). Death was usually precipitated 
by extrahepatic sepsis (52). Conversely, patients exhibiting chronic 
liver disease were found to have decreased survival when compared to 
patients without elevated LFTs (51,53). It is important to state 
that all the studies of liver disease in renal transplant recipients 
were done prior to the cyclosporine era. The complexities inherent 
in assigning an etiology to elevations in LFTs after renal 
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transplantation are best appreciated by a brief consideration of the 
many possible causes of post-transplant hepatitis. 
Although at one time HBV infection was thought to play a major 
role in post-transplant hepatitis, the importance of this agent has 
waned due to the introduction of tests to screen banked blood for HBV 
surface antigen (HBsAg) (51,62,63,66,69). In one large series, for 
example, Ware, et al., found that HBV accounted for only 10% of liver 
disease detected in renal transplant recipients (62). HBV is still 
thought to be an important factor in chronic hepatitis (53,70), 
however. HAV appears to play no role in the development of 
post-transplant hepatic dysfunction (51,62). 
Clearly, then, post-transplant hepatitis in the majority of cases 
is due to non A-non B hepatitis. Although many agents have been 
implicated as the cause of non A-non B hepatitis, in most cases of 
post-transplant hepatitis it is impossible to find an etiology 
(51,53,62,63,65,66). This has lead some authors to conclude that the 
most common cause of hepatitis (especially chronic hepatitis) is 
transfusion associated, viral, non A-non B hepatitis (51,62). 
In the cases where an etiology can be assigned, CMV is the most 
frequently implicated agent. CMV infection is ubiquitous in renal 
transplant recipients with active infection rates between 43 and 92% 
(55). The onset of a large number of CMV infections (as well as CMV 
hepatitis) occurs within the first 2 1/2 months and almost all occur 
by the fourth post-transplant month (54,56,57,58,59,61). Primary CMV 
infection occurs in patients who have no serologic evidence of prior 
CMV exposure and is thought to be primarily transmitted by an 
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allograft from a seropositive donor (54,55). Secondary CMV disease, 
which is more common, happens when the recipient who is seropositive 
pre-transplant reactivates latent CMV, probably as a result of 
immunosuppresive medications (54,55,57,60). Active CMV infection is 
asymptomatic in about two-thirds of cases while only 2%-3% suffer 
fulminant, disseminated terminal disease (54,56,57,59,61). Those 
patients with symptomatic CMV can exhibit a syndrome characterized by 
fever, leukopenia, fatigue, pneumonitis and hepatitis (54,55,56). In 
several large studies of liver disease in renal transplant 
recipients, CMV has been implicated in 18 to 30% of cases (51,62, 
63). Conversely, about 15% of patients with active CMV infection 
develop hepatitis (55,58,61). Liver dysfunction is more common in 
patients with primary CMV infection (55). The degree and extent of 
liver function abnormalities correlates with the magnitude of CMV 
titer rises and with the general severity of the disease (56,64). 
CMV hepatitis has been mostly associated with elevations in trans¬ 
aminases, particulary SGOT (56,61). CMV hepatitis in the renal 
transplant recipient tends to be a transient, self-limited disease 
but fulminant cases progressing to hepatic failure and death have 
been reported (62,63,64,65). Several authors have tried to implicate 
CMV as a cause of chronic HBsAg negative hepatitis in renal 
transplant recipients since liver dysfunction due to CMV has been 
reported to last as long as 20 weeks (56,62,64,65). Although hepatic 
dysfunction and CMV infection often occur concurrently, as Ware, et 
al., point out, care must be taken in implicating CMV. Because CMV 
infection is so common, there is always the possibility that these 
& 
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events overlapped by chance (62). If, however, the onset of liver 
disease is accompanied by a characteristic febrile illness with 
positive cultures and subsequent seroconversion, CMV can be assigned 
as the cause with some certainty (62,65). 
In contrast to CMV, other members of the herpes virus family - 
EBV, HSV and herpes zoster (HZV) - are thought to play a small role 
in post-transplant hepatitis with sporadic cases reported in several 
studies (62,63,65,66). This may in part be due to the fact that 
these viruses are not tested for on a routine basis. As in the case 
of CMV, a large number of renal transplant patients are seropositive 
for these herpes viruses prior to transplantation and often latent 
virus can be reactivated as evidenced by seroconversion (50,54,61,62, 
64,67,68). These viruses also have their onset mainly in the first 
six post-transplant months (54). In the case of HSV and HZV, 
infections are usually cutaneous in nature but can disseminate 
causing fulminant terminal hepatitis (50,54,62,63,66). In the case 
of EBV, infection is most notable for its association with lympho- 
proliterative disorders but may also cause a CMV-like syndrome with 
acute hepatitis (54,67,68). To complicate diagnosis further, there 
has been a suggestion that other herpetic infections can mimic CMV 
since in some patients there may be concurrent rises in antibodies to 
CMV and EBV, HSV or HZV along with the symptoms characteristic of CMV 
(67,68,74). 
In addition to the multiple viral causes of post-transplant 
hepatitis, renal transplant patients often receive a number of 
potentially hepatotoxic drugs including alpha-methyldopa, isoniazid. 
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acetaminophen, furosemide and hydralazine (50). In one study, 
patients recieved a mean of seven proven potentially hepatotoxic 
drugs (71). Prior to the advent of cyclosporine, in fact, 
azathioprine was thought by many to be an important etiologic factor 
in post-transplant liver disease (65,66,71,72). Azathioprine can 
cause a dose-related cholestatic picture and many series have 
reported cases of liver dysfunction which reversed with azathioprine 
reduction or discontinuation (51,62,65,69). Despite this, the 
overwhelming consensus is that azathioprine and drugs in general are 
a minor cause of acute hepatic dysfunction and are of no importance 
in chronic hepatitis (51,62,63,65,66,69,71,72). 
Aside from viruses and drugs, other possible causes of abnormal 
LFTs will only be mentioned and include congestive cardiac failure, 
diabetes mellitus, polycystic disease, biliary tract disease and 
ethanol abuse (50,73,76). 
This brief review is sufficient to underscore the fact that 
multiple etiologies must be at least considered before cyclosporine 
toxicity can be definitively implicated in a case of abnormal LFTs. 
This is especially true of the viral hepatitides which tend to occur 
during the same time period as cyclosporine hepatotoxicity, during 
the first 4 to 6 post-transplant months. Unfortunately, most of the 
studies that have examined cyclosporine hepatotoxicity have not 
detailed which other causes of hepatitis were ruled out, making the 
results difficult to interpret. 
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PURPOSE 
The purpose of this retrospective study was to examine the role 
of cyclosporine in liver disease occurring during the crucial first 6 
months after renal transplantation. Several important questions were 
addressed. First, are all cases of liver dysfunction that occur 
during cyclosporine therapy due to the drug itself? Second, do 
elevated LFTs occur more fequently with cyclosporine than with 
azathioprine immunosuppression? Lastly, which LFTs, if any, reflect 
cyclosporine hepatotoxicity? Since liver disease is an important 
cause of mortality in long-term survivors of renal transplantation, 
answers to these questions may help to elucidate whether cyclosporine 
will aggravate the course of this disease. 
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MATERIALS AND METHODS 
Cyclosporine was introduced at Yale in November of 1983. Up 
until January, 1985 it was used with steroids only in high-risk renal 
transplant recipients, i.e., diabetics, recipients greater than 50 
years of age, recipients of second and third grafts. Since January, 
1985, cyclosporine has been used in all recipients of cadaveric 
kidney transplants. 
Patient Population 
Liver function tests (LFTs) and cyclosporine levels (where 
applicable) were analyzed for all patients (n=56) receiving a renal 
transplant at Yale-New Haven Hospital between August, 1983 and April, 
1985. In order to be included, patients had to have had bimonthly 
LFTs consisting of SGOT and/or SGPT, for the first two months 
following transplantation and monthly LFTs thereafter for at least 
two additional months. Bilirubin levels were also analyzed whenever 
they were available. AP levels were not examined because 
fractionation to determine percent bone activity was not routinely 
performed. Patients were excluded from this study if they had 
chronic elevations in LFTs due to known liver disease prior to 
transplantation. For the purposes of this study, patients were 
followed for a minimum of four months and a maximum of six months. 
Patients were assigned to the cyclosporine treatment group or the 
azathioprine group depending upon which drug was used during the 
second through sixth post-transplant months. Thus, patients in the 

25 
cyclosporine-treated group had to have been started on the drug 
within one month of transplantation and maintained on it for at least 
four consecutive months; likewise for the azathroprine-treated 
group. Four patients were switched from azathioprine to cyclosporine 
between one and four months post-transplant. These patients could 
not be included in either group and were excluded from analysis, 
leaving 52 patients. 
Of 25 cyclosporine-treated patients, six were excluded. Two 
patients had chronically elevated LFTs prior to transplantation - one 
presumed second to polycystic liver disease and the other thought 
second to non A-non B hepatitis. Four additional patients had 
insufficient follow-up (one patient died two months post-transplant, 
one left treatment AMA and two did not have a sufficient number of 
LFTs measured.) One patient who was included in the cyclosporine 
group was also maintained on low-dose azathioprine. There was a 
final total of 19 cyclosporine-treated patients included for 
analysis. 
Of 27 azathioprine-treated patients, twelve were excluded because 
there were an insufficient number of LFTs measured during the 
follow-up period. Four patients had one set of LFTs missing but had 
good follow-up in subsequent months and were included in the study. 
Another patient that was included had only one set of LFTs measured 
in the second post-transplant month, no LFTs in the third month, but 
had increased LFTs in the fifth month. A total of 15 patients thus 




Those patients treated with cyclosporine from the day of 
transplantation received a loading dose of 15 mg/kg orally or .5 
mg/kg intravenously on the day of surgery. Thereafter patients 
received a dose of cyclosporine once or twice per day to approximate 
a serum trough level of 50-150 ng/ml. Cyclosporine levels were 
measured daily while the patient was in the hospital and weekly 
thereafter. Cyclosporine-treated patients were given oral prednisone 
begun at 2 mg/kg/day and tapered to .25 mg/kg/day over the first 
month. 
Patients in the azathioprine group received 2 mg/kg/day with the 
dosage adjusted for leukopenia and infection. Patients also received 
prednisone begun at 4 mg/kg/day tapered to .5 mg/kg/day over the 
first post-transplant month. 
Rejection in all patients was confirmed by renal biopsy and 
treated with pulse steroids (500 mg solumedrol x 3). If the 
rejection was steroid resistant, the patient was then treated with 
two to three weeks of Upjohn Anti thymocyte globulin (ATG), 15 
mg/kg/day, or Ortho monoclonal antibodies against 0KT3 cells for ten 
days. 
Definitions and Data Analysis 
Elevated LFTs were defined as an SGOT or SGPT of greater than 41 
on two consecutive occasions. Total serum bilirubin levels greater 
than 1.5 mg/dl were considered abnormal. For each increase in LFTs 
within the first six post-tranplant months, the patient's hospital 
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and outpatient records were examined for laboratory data, relevant 
symptomatology, medications and other pertinent clinical information. 
Most increases in LFTs were followed up with serum testing for 
HBV and anti-EBV antibody levels. In addition, serum CMV antibody 
titers along with urine and saliva CMV cultures were obtained monthly 
post-transplant for six months on all patients and more frequently if 
LFTs were elevated. 
A number of criteria were used in assessing the cause of an 
elevation in LFTs. A rise in LFTs was considered to be due to CMV 
infection if the rise was associated with or followed by serocon¬ 
version or a four-fold rise in CMV antibody titer and/or positive CMV 
cultures. The infection was considered to be primary if the patient 
was antibody negative pre-transplant and due to reactivation if the 
patient had been antibody positive (antibody titer greater than 
1:8). If a positive serology and elevated LFTs were associated with 
fever (temperature elevation above 100 F for at least two days) 
3 
and/or a depression in WBC (3500 cells/mm for at least two days), 
this was taken to be further evidence of CMV infection. 
An elevation in LFTs was considered to be due to an EBV infection 
if anti-EBV viral capsid antigen (VCAG) titer was greater than 1:160 
and if the anti-EBV early antigen (EAG) titer was greater than 1:20. 
A patient was considered to have an acute HBV infection if the 
increase in LFTs was associated with an HBV screen positive for HBsAg 
and/or IgM antibodies against HBV core antigen. A diagnosis of non 
A-non B hepatitis was entertained if the patient had persistent 
elevations in LFTs, especially SGPT, in the absence of the other 
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viral causes mentioned above. If the elevation was transient, 
however, and associated with a clinical syndrome consistent with a 
viral illness (fever, leukopenia) it was designated as "other viral." 
An elevation in LFTs was considered to be due to drug toxicity if 
it was associated with an elevated drug level and if the LFTs 
decreased with decreasing drug levels or after the drug was 
discontinued. 
Several other causes of elevated LFTs were considered such as 
passive liver congestion due to cardiac failure, sepsis, fatty liver 
associated with diabetes mellitus and ethanol abuse. 
In addition to the analyses described above, average monthly 
SGOT, SGPT and total bilirubin were compared in cyclosporine-treated 
patients versus azathiprine-treated patients. An attempt was made to 
correlate cyclosporine trough levels with SGOT, SGPT and bilirubin. 
Graft loss was defined as nephrectomy, return to dialysis or 
death of the patient. 
Laboratory Methods 
LFTs were measured using the EPOS autoanalyzer. Six patients had 
0 
transaminases measured on serum samples stored at -20 C for anywhere 
from 5 to 22 months after collection. Four patients had one sample 
and two patients had two samples assayed after storage in this 
fashion. Three patients belonged to the cyclosporine group and three 
to the azathioprine group. Serum cyclosporine levels were determined 
by HPLC. The methods used have been described previously (16). 
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Serum CMV titers were measured by a complement fixation technique 
that detects mainly IgG antibody to CMV. An antibody titer above 1:8 
was considered positive. Techniques used to process urine and saliva 
CMV cultures are described elsewhere (75). 
A hepatitis B screen consisted of HBsAg titer, anti-HBsAg titer 
and anti-HBV core titer. If a patient was found to be positive for 
anti-HBV core antibodies, it was determined whether or not they were 
IgM in type. These tests were all performed via an Elisa technique 
using kits from Abbott Laboratories. 
Serum antibodies against EBV antigens were measured using 
indirect immunofluorescence. If a patient had an anti EBV VCAG titer 
greater than 1:160, antibody against EBV-induced early antigens was 
measured. A titer greater than 1:20 was indicative of acute EBV 
infection. 
Statistical Analysis 
Statistical analysis was carried out using SASS and Clinfo series 
of programs. Groups were compared using the Student's T-test and Chi 
square analysis. Linear regression analysis was also employed. All 
results are expressed as the mean t SEM. P values less than or equal 




Baseline characteristics of the cyclosporine treatment group and 
the azathioprine treatment group are compared in Table 1. As 
expected, due to the initial use of cyclosporine only in high-risk 
patients receiving cadaveric grafts, cyclosporine-treated patients 
tended to be older and a larger percentage received cadaveric 
transplants when compared with azathroprine-treated patients. Six 
and 12 month graft and patient survival tended to be higher in the 
azathioprine-treated group but the difference was not statistically 
significant. Again, this is probably due to the initial use of 
cyclosporine in high-risk renal transplant recipients. When all 
patients with liver disease (including two cyclosporine-treated 
patients with known liver disease prior to transplantation) were 
considered together, their one year survival was 82% compared with 
100% for those transplant recipients without liver disease (p = .1). 
Graft survival was 76% vs. 97%, respectively (p = .04). Nineteen 
cyclosporine-treated patients and 15 azathioprine-treated patients 
form the basis for the rest of this report. 
The frequency of elevated LFTs in each group was similar. 
Forty-seven percent (9 patients) of the cyclosporine group versus 40% 
(6 patients) of the azathioprine group (p = .74) developed abnormal 
transaminases during the first 4 to 6 post-transplant months. Peak 
transaminase levels varied from one and one-half to ten times 
normal. Although serum bilirubin levels were not obtained regularly, 




Each patient with elevated LFTs had an identifiable cause for 
their hepatic dysfunction. Graphs of post-transplant transaminases 
including pertinent clinical and laboratory data for each patient 
with elevations can be found in appendix A. The conclusions reached 
from analysis of these graphs are summarized in Tables 2 and 3 and 
are further discussed below. 
Individual Causes of Elevated LFTs 
CMV: CMV, both reactivation and primary disease, was the most 
common identifiable cause of elevated LFTs in this study. Of six 
azathioprine-treated patients with elevated SGOT and/or SGPT, four 
had acute CMV hepatitis as did three out of nine cyclosporine-treated 
patients (p = .31). Conversely, of six azathioprine-treated patients 
with CMV infections, four developed hepatitis as did three of ten 
cyclosporine-treated patients (p = .3). 
All four azathioprine-treated patients with CMV hepatitis and two 
of the three cyclosporine-treated patients were symptomatic with a 
febrile illness and/or leukopenia. Cyclosporine patient #7 was an 
outpatient during his episode of elevated transaminases and there 
were no complaints recorded during any clinic visits. Despite this, 
the peak in his transaminases was so closely related to seroconver¬ 
sion for CMV that this seems the most likely cause. 
Three of the four azathioprine patients (#1,2,4) with CMV 
hepatitis were being treated for rejection with ATG during or just 
prior to developing CMV. In none of these patients could use of ATG 
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be related to elevated LFTs. In patients #1 and #4, peak elevations 
in LFTs did not occur during ATG treatment. In patient #2, eleva¬ 
tions in transaminases did occur only during treatment with ATG. 
Although ATG can cause a hypersensitivity type reaction (similar to 
serum sickness) and thus could cause elevated LFTs, patient #2 had no 
evidence of this. The patient's fever pre-dated and post-dated ATG 
treatment and was probably due to infection with CMV. 
In both groups, CMV hepatitis tended to occur between one and 
three months post-transplant with elevations in both SGOT and SGPT. 
SGPT tended to be greater than SGOT and could rise as high as 300 to 
400 IU while SGOT generally peaked between 100 to 200 III. In both 
groups, elevations in SGPT could persist for up to two to three 
months. 
Cyclosporine-treated patient #9 with symptomatic CMV-hepatitis in 
the second and third post-transplant months is described in detail 
elsewhere (77) but deserves further comment here. During the first 
post-transplant week, she had an elevated SGOT with normal total and 
direct bilirubin while being treated for chest pain in the Coronary 
Care Unit. The patient had a long history of congestive heart 
failure which probably accounted for this initial transient elevation 
in SGOT. Later in her post-transplant course, she went on to develop 
an intestinal lymphoma which regressed with discontinuation of 
cyclosporine (77). Interestingly, the patient was not seropositive 
for EBV yet molecular hybridization studies showed that the tumor 
cells contained the EBV genome (77). 
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Other Viral/Non A-Non B: After CMV, the most common cause of 
elevated LFTs was a viral illness that could not be identified as CMV 
or HBV. In azathioprine patient #3 and in cyclosporine patient #11, 
the elevation was transient while in cyclosporine-treated patients 
#14 and #15, the hepatic dysfunction was chronic. 
The cause of elevated transaminases in patients #3 and #11 was 
designated as other viral because of the temporal association with 
fever and leukopenia. EBV infection was not ruled out in either 
patient. Non A-non B hepatitis could not be definitely ruled out in 
patient #11 since the elevation in LFTs preceded the symptoms by 13 
days. Also, the patient's review of systems was positive for 
jaundice prior to transplantation. 
Cyclosporine-treated patients #14 and #15 had elevations in SGOT 
and especially SGPT throughout the follow-up period. This pattern is 
consistent with non A-non B hepatitis. In patient #14 the initial 
increase in SGOT and SGPT was accompanied by a febrile illness which 
pre-dated and post-dated ATG therapy for rejection. Initially his 
3 
WBC was greater than 20,000 cells/mm but he developed leukopenia 
immediately after ATG therapy ended. There was no evidence of 
chronically elevated LFTs prior to transplantation. Patient #15 had 
a post-transplant course complicated by a perforated intestinal 
diverticula requiring i1eocolectomy and ileostomy and then further 
surgery for intestinal obstruction. Although the patient had 
evidence of sepsis during part of this time, elevated LFTs preceded 
these events by many weeks. The patient also developed 
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steroid-induced diabetes mellitus post-transplant, but again elevated 
LFTs preceded this. 
Sepsis: Azathioprine-treated patient #6 and cyclosporine-treated 
patient #8 had elevated LFTs associated with terminal medical 
events. Patient #6 was a 34 year old male who was admitted for re¬ 
jection of his living-related renal graft during the fifth post¬ 
transplant month. During treatment with monoclonal antibodies 
against 0KT3 cells, the patient began a progressive, down-hill course 
marked by elevated SGOT and SGPT, a spreading cutaneous herpetic 
infection, a question of an infiltrate on chest x-ray, disseminated 
intravascular coagulation, and decreasing mental status. Of note, 
the patient was treated with IV acyclovir for disseminated herpes 
zoster during the second post-transplant month and previously had an 
episode of cutaneous herpes simplex. Just prior to his demise, blood 
cultures were positive for gram negative organisms and CSF was FAMA 
positive (indicative of herpetic infection). Elevated LFTs in this 
patient can be attributed to a disseminated herpetic infection with 
bacterial sepsis. 
Patient #8 was a 32 year old man with brittle insulin-dependent 
diabetes mellitus who was admitted during the third post-transplant 
month for treatment of rejection and for a left arm abscess. His 
hospital course was marked by sepsis with disseminated intravascular 
coagulation and he ultimately died after a hypoglycemic seizure. 
Relatively small elevations of SGOT with marked hyperbilirubinemia 
during this time were probably due to sepsis. Earlier solitary 
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elevations in SGOT were probably as a result of extremely elevated 
blood sugars (generally greater than 700 mg/%). 
Mi seel 1aneous: The remaining two cyclosporine-treated patients 
had more than one possible cause for elevated LFTs and each will be 
discussed briefly. 
Patient #10, a 47 year old black male with a history of 
congenital heart disease, had a post-transplant course notable for 
several mild elevations (generally less than 60) in SGPT. During one 
elevation the patient presented with ataxia characteristic of 
dilantin toxicity and an elevated dilantin level. Dilantin-induced 
hepatitis, however, is usually associated with a hypersensitivity 
reaction which this patient did not have (78). Also, the patient had 
persistent elevations in SGPT even after dilantin levels returned to 
normal. Although the patient did have a four-fold rise in his 
anti-CMV antibody, the waxing and waning in SGPT is not characteris¬ 
tic of CMV hepatitis seen in the other patients. A hepatitis B 
screen was not done but the patient was HBV negative pre-transplant 
and acute hepatitis B infection does not usually present with mild 
chronic elevations in SGPT (79). This patient also developed steroid 
induced diabetes mellitus and could have had elevated LFTs on the 
basis of fatty liver. Chronic elevations in SGPT along with the 
patient's history of cardiac surgery and probable transfusions, make 
non A-non B hepatitis the most likely possibility. 
Patient #12, a 44 year old male, developed transient elevations 
in SGOT and SGPT while being treated with ATG in the sixth post¬ 
transplant month. The patient had fevers and leukopenia, generally 
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but not exclusively associated with ATG therapy. Concommitantly, he 
developed a pulmonary infiltrate, rales, weight gain and pedal edema 
which seemed to resolve with Lasix. Transiently elevated LFTs in 
this patient could have been due to cardiac failure but a viral 
illness cannot be definitely excluded because of the possibility of a 
febrile illness not caused by ATG. ATG seems to be an uniikely cause 
of elevated transaminases in this patient since he had no other signs 
of a hypersensitivity reaction. 
Comparison of Mean Monthly LFTs 
The average SGOT, SGPT and total bilirubin were calculated for 
each patient by month and then the means were compared in the 
cyclosporine group versus the azathioprine group. Due to the small 
number of patients in each group and the similar frequency of 
clinical hepatitis in each group, all patients were included. 
Patients could have anywhere from none to 16 determinations for any 
given month. As seen in Figures 1A and IB, there was no significant 
difference in SGOT or SGPT between cyclosporine and azathioprine 
groups during any post-transplant month. Total bilirubin (Figure 1C) 
tended to be higher in the cyclosporine group and the result was 
statistically significant during post-transplant months one and 
three. The higher mean total bilirubin for the azathioprine group in 
month 6 is due to patient #6, described previously, who had a mean 
bilirubin for that month of 5.46 mg/dl while dying of sepsis. This 
value was five times higher than the other 5 patients and when this 
value was excluded, the mean was .79 ± .15 (p = .24) compared with 
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the cyclosporine group. When patients with elevated transaminases 
were excluded, the same trends were found. 
Correlation of LFTs With Cyclosporine Levels 
Mean monthly cyclosporine trough levels were calculated for each 
patient and then averaged. A patient could have any where from none 
to 30 determinations for any given month. As can be seen in Figure 
2, cyclosporine levels tended to decline with time, especially after 
the first two post-transplant months. The 9 cyclosporine-treated 
patients with liver dysfunction did not have higher serum trough 
levels of the drug during any post-transplant month when compared to 
patients with normal LFTs (Table 4). 
In order to detect a dose-dependent effect of cyclosporine, a 
linear regression analysis was used to correlate LFTs with the 
cyclosporine trough level measured on the same day. The data for 
direct and total bilirubin is summarized in Table 5. 
When all patients were considered (even those with clinical 
hepatitis), no correlation was found between cyclosporine trough 
levels and either SGOT (r = .04, p = .44), SGPT (r = .001, p = .99), 
direct bilirubin (r = .04, p = .60) or total bilirubin (r = .06, p = 
.40), when six months of data was examined. However, a correlation 
between direct bilirubin or total bilirubin became apparent when the 
first two post-transplant months were analyzed. This became even 
more prominant when those patients with elevated transaminases due to 
other causes were excluded. There was no correlation between 
cyclosporine levels and either SGOT or SGPT. 
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DISCUSSION 
Prior to the cyclosporine era, chronic liver failure was found to 
be the most common cause of death in renal transplant recipients with 
grafts functioning more than 5 years (52). Since cyclosporine 
therapy has been associated with hepatic dysfunction in some reports, 
this study was undertaken to examine the role of cyclosporine in 
post-transplant liver disease. 
Because of the retrospective nature of this study, LFTs and 
particularly bilirubin levels, were not obtained regularly. As a 
general rule, once patients were discharged from the hospital, LFTs 
were measured more frequently when patients became symptomatic. 
Since liver dysfunction can be entirely asymptomatic, the potential 
for an artificially low incidence of liver disease existed. This was 
especially true for azathioprine-treated patients who had fewer LFTs 
measured. We attempted to minimize this detection bias by excluding 
patients with an insufficient number of LFTs. This resulted in a 
small sample size which should be kept in mind when considering these 
results. 
The issue of cyclosporine hepatotoxicity was addressed in two 
ways. In the first part of this study the incidence and causes of 
elevated transaminases were compared in cyclosporine-treated patients 
versus azathioprine-treated patients. This type of comparison might 
have allowed us to detect a subtle effect of cyclosporine in 
influencing liver disease. Our results show, however, that there is 
no difference in the incidence of liver dysfunction between the 
cyclosporine group (47%) and the azathioprine group (40%). 
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Furthermore, a careful analysis of all available data revealed an 
identifiable etiology in each case of elevated transaminases. In the 
cyclosporine group, cyclosporine dosages were not adjusted in 
response to elevated LFTs and in no case could cyclosporine be 
implicated as the cause of hepatic dysfunction. Despite small 
numbers, it appeared that the causes of hepatitis were no different 
in cyclosporine-treated patients versus azathioprine-treated 
patients. If both groups are considered together, our results are 
similar to those of other authors studying the causes of 
post-transplant hepatitis. 
In this series, as in others, HBsAg negative, viral hepatitis was 
the most common cause of elevated LFTs (51,62,63,65,66). In fact, in 
no patient could HBV be implicated as the cause of liver 
dysfunction. Although HAV was seldom tested for, other authors have 
found that HAV plays no role in post-transplant hepatitis (51,62). 
Of 12 patients with viral hepatitis CMV infection was the most 
commonly identifiable cause (7 patients) of acutely elevated 
transaminases. CMV hepatitis always occurred within the first three 
post-transplant months and elevated LFTs could persist for up to 
three months. These characteristics are similar to those reported 
previously (51,56,62,63,64,65). The contributing role of other 
herpes viruses in these patients cannot be ruled out. As pointed out 
by Marker et al. and Balfour et al., seroconversion for EBV, HSV or 
HZV often accompanies active CMV infection (67,74). Unfortunately 
none of these viruses was tested for on a routine basis. 
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Two additional patients had a viral syndrome characterized by 
transient elevations in transaminases with leukopenia and/or fever 
that could not be identified as CMV or HBV. As stated above, 
serologic tests for viruses such as EBV, HSV or HZV were not 
routinely obtained, thus these viruses could not be definitively 
ruled out as etiologic agents. Despite this, most studies have found 
that herpes viruses (other than CMV) play a minor role in 
post-transplant liver disease (62,63,64,66). In this study, only one 
patient developed a fulminant, disseminated herpetic infection with 
accompanying hepatitis (and bacterial sepsis). This type of course 
in renal transplant recipients with HSV or HZV has been reported 
previously (50,54,62,63,66). 
In at least two patients, hepatic dysfunction was of a chronic 
nature and transfusion associated non A-non B hepatitis was the most 
likely cause. With a longer follow-up period, this diagnosis might 
have been possible in other patients as well, especially since other 
studies have implicated non A-non B hepatitis as the most frequent 
cause of chronic liver dysfunction after renal transplantation 
(51,53,62,66). 
In addition to cyclosporine and for that matter azathioprine, 
patients in this study were on a variety of drugs with hepatotoxic 
potential including ATG, dilantin, hydralazine, alpha-methyldopa and 
furosemide. Drug dosages were not adjusted in response to LFTs and 
in most patients this did not affect the course of hepatic 
dysfunction. One patient (#10) did present with ataxia due to 
dilantin toxicity and shortly thereafter with elevated transaminases 
\ 
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as well. Nevertheless, dilantin was probably not the cause of 
hepatic dysfunction in this patient. He had been on dilantin for 
many years without any history of liver dysfunction and his 
transaminases were elevated even after dilantin levels returned to 
normal. Also, dilantin hepatotoxicity is usually due to a 
hypersensitivity reaction which this patient did not have. In 
addition, several patients were treated with ATG during periods of 
abnormal liver function. In all but one of these patients (#12) a 
viral cause (CMV) of hepatitis was identified. ATG can cause 
elevated LFTs on the basis of a hypersensitivity reaction akin to 
serum sickness. None of these patients, however, had any other signs 
of this type of reaction. Our results are thus in agreement with 
those of other published reports showing that medications play only a 
very minor role in liver disease after renal transplantation 
(51,62,63,65,66,69). 
In sum, cyclosporine does not appear to alter the spectrum of 
liver disease in patients receiving renal allografts. The type of 
analysis described above highlights the complexity involved in 
assigning an etiology to post-transplant liver dysfunction. 
Cyclosporine hepatotoxicity was examined in another type of 
analysis. Mean monthly LFTs were compared in cyclosporine- versus 
azathioprine-treated patients and an attempt was made to correlate 
serum cyclosporine trough levels with LFTs. Cyclosporine levels were 
measured using the HPLC method which is thought to be more reliable 
in the setting of liver dysfunction (15). All determinations were 
performed on serum which may more accurately reflect free drug levels 
(16). 
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Not surprisingly, no association was found between transaminase 
levels and cyclosporine therapy. The 9 cyclosporine-treated patients 
with elevated LFTs did not have higher cyclosporine levels during any 
post-transplant month when compared with those patients having normal 
LFTs. Nor was there any consistent difference in mean monthly SGOT 
or SGPT in the cyclosporine group versus the azathioprine group. 
Finally, serum cyclosporine levels could not be correlated with SGOT 
or SGPT using a linear regression analysis even when the 9 patients 
with other causes for elevated transaminases were excluded. 
Although clinical hyperbilirubinemia in the absence of elevated 
transaminases did not occur, there was evidence of subclinical 
hepatic dysfunction in cyclosporine-treated patients. Total serum 
bilirubin levels were higher (though still within the normal range) 
in cyclosporine-treated patients versus azathioprine-treated patients 
during the early post-transplant months. The difference was 
statistically significant during months 1 and 3. Furthermore, 
cyclosporine levels were correlated with both direct bilirubin and 
total bilirubin during the first two post-transplant months when 
cyclosporine trough levels were highest. The correlation became 
stronger when the 9 patients with other causes for elevated LFTs were 
excluded. 
Although the correlation of direct bilirubin with cyclosporine 
levels is suggestive of decreased bile flow, it is important to 
distinguish between isolated hyperbilirubinemia and true cholesta¬ 
sis. In this study the specific tests needed to clarify this point - 
AP (liver isoenzyme), 5'-nucleotidase, gammaglutamyl transpeptidase 
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or serum bile acid levels - were not obtained and further work is 
needed in this regard. The reports of several authors, however, have 
addressed this issue. Rotolo et al., studying isolated, perfused rat 
livers, found that cyclosporine in doses of 2 mg/kg and 20 mg/kg 
decreased bile flow and bile acid secretion (80). Schade et al. 
prospectively measured fasting bile salt levels in 11 cyclosporine- 
treated heart transplant recipients and found them to be markedly 
elevated despite normal AP levels (48). Finally, Lorber et al. noted 
an increased incidence of cholelithiasis in cyclosporine-treated 
patients compared with azathioprine-treated patients (47). From 
these data it seems that hyperbilirubinemia in cyclosporine-treated 
patients is probably indicative of true cholestasis. 
Our findings with regard to hyperbilirubinemia are similar to 
those of other authors in that a relationship between cyclosporine 
blood levels and serum bilirubin levels was detected in the early 
post-transplant period (9,39,43, 49). The magnitude of hyperbili¬ 
rubinemia, however, was not the same. For example, Laupacis, et al ., 
Klintmalm, et al., and Keown, et al., all found that between 8.3% and 
19.6% of their cyclosporine-treated patients developed overt 
hyperbilirubinemia usually within the first post-transplant month 
(9,39,41,42,43). There are several possible explanations as to why 
overt hyperbilirubinemia was not detected in this study. First, most 
of the hepatotoxic effects of cyclosporine have been observed early. 
Lorber, et al., reported that 61% of such episodes began during the 
first post-transplant week (47). Since bilirubin levels were not 
measured regularly, it is possible that this effect was missed. 
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Alternatively, cyclosporine levels at this institution were kept 
quite low. Even during the first post-transplant month the mean 
cyclosporine level was only 121 ± 15 ng/ml. Although it is difficult 
to compare because other centers used the RIA technique, serum 
cyclosporine trough levels in other studies were generally kept 
between 100 and 400 ng/ml with levels rising above 600 ng/ml during 
hepatotoxic episodes (39,41,43). Hyperbilirubinemia may have been 
avoided at this center by keeping cyclosporine levels low. Further 
support for this theory comes from the University of Minnesota where 
cyclosporine levels were kept between 100 and 200 ng/ml (HPLC). 
These authors found no increase in the incidence of hyperbili¬ 
rubinemia in cyclosporine-treated patients versus azathioprine- 
treated patients (19). 
Despite these differences, findings from this study and others 
suggest that serum bilirubin levels (and not transaminases) are the 
more important parameter in detecting cyclosporine hepatotoxicity 
(39,42,44,45,48). Only Maddux, et al., and Lorber, et al. have 
reported that cyclosporine immunosuppressive therapy is associated 
with elevated transaminases (46,47). In the two types of analyses 
described above we could find no evidence for this association. In 
this study, every instance of elevated transaminases was analyzed in 
an depth manner with a review of all clinical and viral data 
available. In every case an etiology other than cyclosporine was 
identified. Furthermore, there was no correlation between serum 
cyclosporine levels and transaminases. McMaster, et al., who 
undertook a similar type of analysis, obtained the same results. Not 
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only was there was no difference in the incidence of elevated LFTs in 
cyclosporine-treated patients versus azathioprine-treated patients, 
but a careful review revealed that, as in the series reported here, 
infection was the most common cause of liver dysfunction in both 
groups. Both Maddux et al., and Lorber et al. do state that patients 
with other causes of hepatitis were excluded. Given the complexity 
of this issue, however, the details of this process were not 
adequately described. For example, Lorber et al. report that 49% of 
466 patients developed cyclosporine hepatotoxicity. With the 
ubiquity of CMV it would be surprising if CMV infection were absent 
in this large a proportion of renal transplant recipients. 
Additional information would be essential in deciding whether all 





In sum, cyclosporine appears to play a minor role in the genesis 
of liver disease after renal transplantation. Neither the frequency 
nor the causes of elevated transaminases differs between 
cyclosporine-treated patients and azathioprine-treated patients. 
Mean levels of SGOT and SGPT are not significantly higher in 
cyclosporine-treated patients and there is no correlation between 
either enzyme and cyclosporine trough levels. Elevated transaminases 
do not appear to be a specific marker for cyclosporine hepatotoxicity 
but rather due to viral hepatitis which is prevalent after renal 
transplantation. 
The fact that bilirubin levels are higher (though still within 
the normal range) in cyclosporine-treated patients versus 
azathioprine-treated patients during the first few post-transplant 
months does, however, suggest that the drug can cause mild cholesta¬ 
tic hepatic dysfunction. This is further supported by a correlation 
between cyclosporine trough levels and direct and total bilirubin 
levels. It is possible that when mean serum cyclosporine trough 
levels are kept well under 200 ng/ml, as in this study, this is of 
little clinical significance since bilirubin levels remain within the 
normal range. 
The advent of cyclosporine has not changed the characteristics of 
post-transplant liver disease that existed in the azathioprine era. 
Viral hepatitis is still the most common cause of abnormal liver 
function in renal transplant recipients treated with either cyclo¬ 
sporine or azathioprine. 
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Cyclosporine Azathioprine P Value 
Total Number of Patients 
Mean Age (years) 
% with Diabetes 
% Cadaveric Transplant 
% First Renal Transplant 
6 Month Graft Survival (%) 
6 Month Patient Survival (%) 
12 Month Graft Survival (%) 
12 Month Patient Survival (%) 
19 15 
47±2 35±2 .0008 
26 13 .43 
100 47 < .0004 
84 87 1.00 
89 100 .49 
89 100 .49 
84 93 .61 
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MEAN MONTHLY CYCLOSPORINE LEVELS IN 









(n = # 
of patients) 
P Vali 
1 108 ± 22 
(9) 
133 ± 19 
(10) 
.41 
2 114 ± 30 
(9) 
97 ± 12 
(10) 
.60 
3 78 ± 9 
(9) 
72 ± 8 
(10) 
.59 
4 53 ± 6 
(9) 
62 ± 11 
(10) 
.50 
5 77 ± 14 
(6) 
84 ± 14 
(10) 
.74 
6 75 ± 11 
(4) 






CORRELATION OF CYCLOSPORINE LEVELS WITH 
DIRECT AND TOTAL BILIRUBIN LEVELS 
Direct Bi1irubin Total Bilirubin 
All patients 
(2 months of data) r = .40, p < .001 r = .30, p = .001 
All patients 
(6 months of data) r = .04, p .60 r = .06, p = .40 
Patients with normal 
transaminases 
(2 months of data) 
r = .74, p < .001 r = .41, p = .003 
Patients with normal 
transaminases 
(6 months of data) 




Figure 1: Mean Monthly LFTs in Cyclosporine-Treated Patients Vs 
Azathioprine-Treated Patients. 
An average monthly SGOT (A), SGPT (B) or total bilirubin 
(C) level was calculated for each patient (N). There were 
anywhere from 2 to 16 monthly determinations for each 
patient. The mean value + SEM for each month was compared 
in the cyclosporine group (A —A ) versus the 
azathioprine group (q-□ ): P < .05 
MEAN SGOT IU/ML 




TOTAL BILIRUBIN MG/DL 




Figure 2: Mean Monthly Cyclosporine Trough Levels. 
Cyclosporine trough levels were measured on serum using 
High-Performance Liquid Chromatography. An average 
monthly cyclosporine trough level was calcualted for each 
patient (N). There were anywhere from 2 to 30 monthly 
determinations for each patient. Mean ± SEM cyclosporine 
trough levels during post-transplant months 2, 3, 4, 5 and 
6 were compared with the level during month 1. 
CYLCOSPORINE TROUGH LEVEL(ng/ml) 
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Clinical Data for Nine Cyclosporine-Treated Patients and 





D-O-D : SGOT 
-&-A : SGPT 
CMV: Cytomegalovirus Serology 
HBV: Hepatitis B Virus Serology 
EBV: Epstein-Barr Virus Serology 




MCA: Ortho monoclonal antibodies 
RLL: Right lower lobe 
L: Left 
Wgt: Weight 
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